Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Announce Quarterly Sales of $45.88 Million

Equities analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $45.88 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest sales estimate coming in at $56.70 million and the lowest estimate coming in at $38.80 million. Alnylam Pharmaceuticals posted sales of $29.91 million during the same quarter last year, which suggests a positive year-over-year growth rate of 53.4%. The company is scheduled to issue its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $185.52 million for the current year, with estimates ranging from $113.10 million to $236.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $420.05 million, with estimates ranging from $307.77 million to $514.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. During the same period in the previous year, the business earned ($1.22) EPS. The company’s revenue was up 52.0% on a year-over-year basis.

Several brokerages have issued reports on ALNY. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Leerink Swann boosted their target price on shares of Alnylam Pharmaceuticals to $90.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. BMO Capital Markets boosted their target price on shares of Alnylam Pharmaceuticals from $106.00 to $119.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. Cantor Fitzgerald reissued a “buy” rating and set a $135.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, April 9th. Finally, Svb Leerink boosted their target price on shares of Alnylam Pharmaceuticals from $65.00 to $70.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $130.24.

Shares of NASDAQ:ALNY opened at $68.07 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $124.21. The firm has a market cap of $7.33 billion, a price-to-earnings ratio of -8.99 and a beta of 2.53.

In other news, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the transaction, the director now directly owns 250,633 shares in the company, valued at approximately $22,113,349.59. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Royal London Asset Management Ltd. boosted its holdings in Alnylam Pharmaceuticals by 16.7% in the fourth quarter. Royal London Asset Management Ltd. now owns 66,803 shares of the biopharmaceutical company’s stock worth $4,703,000 after purchasing an additional 9,566 shares in the last quarter. Gateway Investment Advisers LLC boosted its holdings in Alnylam Pharmaceuticals by 17.3% in the fourth quarter. Gateway Investment Advisers LLC now owns 4,531 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 667 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 332.9% in the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 263 shares in the last quarter. Frontier Capital Management Co. LLC boosted its holdings in Alnylam Pharmaceuticals by 3,071.0% in the fourth quarter. Frontier Capital Management Co. LLC now owns 197,869 shares of the biopharmaceutical company’s stock worth $14,427,000 after purchasing an additional 191,629 shares in the last quarter. Finally, Coronation Fund Managers Ltd. bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $11,789,000. Institutional investors and hedge funds own 87.89% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply